Lipe & Dalton Makes New Investment in Boston Scientific Corporation $BSX

Lipe & Dalton purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,300 shares of the medical equipment provider’s stock, valued at approximately $482,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Kelleher Financial Advisors acquired a new position in shares of Boston Scientific during the 2nd quarter valued at about $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific in the 4th quarter valued at $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Boston Scientific during the 1st quarter worth $28,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is currently owned by insiders.

Boston Scientific Stock Down 5.9%

Shares of BSX stock traded down $2.80 on Tuesday, hitting $45.00. The stock had a trading volume of 29,020,296 shares, compared to its average volume of 18,520,377. The stock’s 50 day moving average is $47.04 and its 200-day moving average is $55.18. The firm has a market capitalization of $65.22 billion, a price-to-earnings ratio of 18.22, a P/E/G ratio of 1.10 and a beta of 0.57. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

A number of research firms have issued reports on BSX. TD Cowen reissued a “buy” rating and set a $56.00 price target on shares of Boston Scientific in a research report on Tuesday, August 25th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. BTIG Research reduced their price target on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, July 29th. UBS Group dropped their price objective on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific said manufacturing and shipping operations are recovering, which could limit the disruption’s longer-term impact. The company also expects seven product launches and cost savings to support a recovery by 2028. Boston Scientific’s 2026 Growth Outlook Weakens: Is Recovery Ahead?
• Neutral Sentiment: The company has not quantified the cyberattack’s full financial impact or provided a replacement forecast, leaving investors uncertain about the duration of operational disruptions and the pace of recovery. Boston Scientific says cyberattack likely to hurt 2026 sales, profit
• Negative Sentiment: Boston Scientific now expects it will not meet its previously issued 2026 sales and earnings guidance, including its third-quarter and full-year targets. The warning represents a material downgrade from its earlier outlook and is the main catalyst for the stock’s decline. Boston Scientific Says It Won’t Meet 2026 Guidance After Cyberattack
• Negative Sentiment: Separately, analysts cited pressure on the WATCHMAN and electrophysiology businesses, weakening the company’s near-term growth outlook even before the cyberattack’s effects are fully known. Boston Scientific’s 2026 Growth Outlook Weakens: Is Recovery Ahead?

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.